Target on lung cancer cell

The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations.

The therapies are the first to be approved specifically for the treatment of patients with BRAF V600E mutation-positive metastatic NSCLC.

Learn More